Jaume Trape1,2, Jordi Aligue2,3,4, Mireia Vicente5, Anna Arnau6, Antonio San-Jose7, Josep Ordeig4, Roser Ordeig4, Mariona Bonet4, Andres Abril4, Omar El-Boutrouki4, Carolina Gonzalez-Fernandez8, Maria Sala8, Cristina Figols8, Elisabeth Gonzalez-Garcia5, Lourdes Montsant8, Domingo Ruiz4. 1. Laboratory Medicine Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain; jtrape@althaia.cat. 2. Faculty of Medicine, Universitat de Vic, Universitat Central de Catalunya, Vic, Spain. 3. Central Catalonia Chronicity Research Group (C3RG), Internal Medicine Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain. 4. Internal Medicine Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain. 5. CAP Manresa 2 Institut Catala de la Salut Barcelona, Barcelona, Spain. 6. Clinical Research Unit, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain. 7. Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain. 8. Laboratory Medicine Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
Abstract
BACKGROUND/AIM: Paraneoplastic syndrome symptoms include isolated involuntary weight loss (IIWL). The differential diagnosis of cancer from other diseases may require a significant number of tests. Tumour markers (TMs) can be used for the diagnosis and stratification of patients according to cancer risk. PATIENTS AND METHODS: This study included 606 patients (48% females) seen at the rapid diagnostic unit for IIWL. We determined the levels of TMs carcinoembryonic antigen, carbohydrate antigen 19-9, soluble fragments of cytokeratin 19, carbohydrate antigen 15-3, carbohydrate antigen 125, neuron specific enolase, alpha-fetoprotein, prostatic specific antigen using the multiparametric analyser COBAS 601. Two cut-off points were established, the upper reference limit described by the manufacturer and a high cut-off point suggested by Molina et al., to stratify patients according to cancer risk. RESULTS: Patients were classified according to TM levels as follows: I) all TMs below the upper reference limit; II) highest number of TMs between the two cut-offs; III) at least one TM above the higher cut-off. The odds ratio for malignancy was 4.3 for group II and 248 for group III. These results indicate that when at least one TM is above the higher cut-off, neoplasia is highly probable. CONCLUSION: TM determination allowed to establish cancer risk in patients with IIWL.
BACKGROUND/AIM: Paraneoplastic syndrome symptoms include isolated involuntary weight loss (IIWL). The differential diagnosis of cancer from other diseases may require a significant number of tests. Tumour markers (TMs) can be used for the diagnosis and stratification of patients according to cancer risk. PATIENTS AND METHODS: This study included 606 patients (48% females) seen at the rapid diagnostic unit for IIWL. We determined the levels of TMs carcinoembryonic antigen, carbohydrate antigen 19-9, soluble fragments of cytokeratin 19, carbohydrate antigen 15-3, carbohydrate antigen 125, neuron specific enolase, alpha-fetoprotein, prostatic specific antigen using the multiparametric analyser COBAS 601. Two cut-off points were established, the upper reference limit described by the manufacturer and a high cut-off point suggested by Molina et al., to stratify patients according to cancer risk. RESULTS: Patients were classified according to TM levels as follows: I) all TMs below the upper reference limit; II) highest number of TMs between the two cut-offs; III) at least one TM above the higher cut-off. The odds ratio for malignancy was 4.3 for group II and 248 for group III. These results indicate that when at least one TM is above the higher cut-off, neoplasia is highly probable. CONCLUSION: TM determination allowed to establish cancer risk in patients with IIWL.
Authors: Jaume Trapé; Maria Sala; Fina Franquesa; Josep M Ordeig; Josep M Soler-Bel; Eva Bustamante; Rafael Pérez; Jordi Aligué; Jesús Montesinos; Anna Arnau; Roser Ordeig-Villanueva Journal: Clin Chem Lab Med Date: 2015-02 Impact factor: 3.694
Authors: Moisés Casarrubias-Ramírez; Josué Emiliano López-Martínez; Luis Francisco Pineda-Galindo; Ana Laura Carrillo-González; Edgar Zavaleta-Ramírez; Felipe Iniestra-Flores Journal: Rev Med Inst Mex Seguro Soc Date: 2019-05-02
Authors: Xavier Bosch; Rafael Molina; Ramon Marrades; Josep M Augé; Martina Pellicé; Alfonso López-Soto Journal: Eur J Clin Invest Date: 2021-03-03 Impact factor: 4.686